共 50 条
- [21] Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)McArthur, Grant A.Gutzmer, RalfStroyakovskiy, DaniilGogas, HelenRobert, CarolineProtsenko, SvetlanaPereira, Rodrigo PerezEigentler, ThomasRutkowski, PiotrDemidov, Lev V.Zhukova, Natalia V.Schachter, JacobYan, YibingCaro, IvorHertig, ChristianXue, ClorisKusters, LiekeAscierto, Paolo AntonioLewis, Karl D.
- [22] Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Dummer, ReinhardQueirolo, PaolaGuijarro, Ana Maria AbajoHu, YouyouWang, DaoAzevedo, Sergio JobimRobert, CarolineAscierto, Paolo AntonioChiarion-Sileni, VannaPronzato, PaoloSpagnolo, FrancescoMujika, KarmeleLiszkay, GabriellaMerino, Luis De la CruzTawbi, Hussein A.
- [23] Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) plus vemurafenib (VEM) in the phase 3 coBRIM studyEUROPEAN JOURNAL OF CANCER, 2015, 51 : S722 - S723McArthur, G.Larkin, J.Dreno, B.Ascierto, P.Liszkay, G.Maio, M.Mandala, M.Demidov, L.Stroyakovskiy, D.Thomas, L.De la Cruz-Merino, L.Atkinson, V.Dutriaux, C.Garbe, C.Wongchenko, M.Hsu, J.Koralek, D.Rooney, I.Yan, Y.Ribas, A.
- [24] A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma (COMBI-i)ANNALS OF ONCOLOGY, 2017, 28Gasal, E.Arance Fernandez, A. M.Ascierto, P. A.Atkinson, V.Dummer, R.Flaherty, K. T.Grob, J-J.Hansson, J.Hassel, J.Larkin, J.Lebbe, C.Long, G. V.Lorigan, P.Miller, W.Nathan, P.Ribas, A.Robert, C.Schadendorf, D.Tawbi, H.Upalawanna, A.
- [25] Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive melanoma with central nervous system (CNS) metastases (mets): Final results and exploratory biomarker analysis from the phase 2 TRICOTEL studyJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Dummer, ReinhardLevesque, MitchellBellini, ElisaChen, MarissaHu, YouyouWong, TiffanyStassen, KatjaDuhard, PaulineYan, YibingTawbi, Hussein A.
- [26] PACIFIC: a double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLCONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 270 - 270Schulz, C.Laack, E.Wolff, T.Rueckert, A.Reck, M.Faehling, M.Fischer, J. R.de Wit, M.
- [27] Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled studyBreast Cancer Research and Treatment, 2020, 182 : 689 - 697Binghe XuWei LiQingyuan ZhangZhimin ShaoQiao LiXiaojia WangHuiping LiTao SunYongmei YinHong ZhengJifeng FengHong ZhangGuiyuan LeiEleonora Restuccia
- [28] Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled studyBREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (03) : 689 - 697Xu, BingheLi, WeiZhang, QingyuanShao, ZhiminLi, QiaoWang, XiaojiaLi, HuipingSun, TaoYin, YongmeiZheng, HongFeng, JifengZhang, HongLei, GuiyuanRestuccia, Eleonora
- [29] A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral Talactoferrin in Combination with Carboplatin and Paclitaxel in Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung CancerJOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : 1098 - 1103Digumarti, RaghunadharaoWang, YenyunRaman, GanapathiDoval, Dinesh C.Advani, Suresh H.Julka, Pramod K.Parikh, Purvish M.Patil, ShekharNag, ShonaMadhavan, JayaprakashBapna, AjayRanade, Annantbhushan A.Varadhachary, AtulMalik, Rajesh
- [30] The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 studyJOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)Dummer, ReinhardWelti, MicheleRamelyte, Egle